Validation of a New Glucocorticoid-specific Patient-Reported Outcome Questionnaire (the Steroid PRO)

Overview

Journal Ann Rheum Dis

Specialty Rheumatology

Date 2023 Nov 10

PMID 37949468

Authors

Susan Bridgewater

Mwidimi Ndosi

Jill Dawson

Pamela Richards

Christine Silverthorne

Emma Dures

Susan M Goodman

Catherine Hill

Sarah L Mackie

Joanna C Robson

Affiliations

Soon will be listed here.

Abstract

Objectives: Glucocorticoids used in the treatment of inflammatory rheumatic conditions can impact on health-related quality of life. An underpinning qualitative study developed a long-list of candidate items for a treatment-specific patient-reported outcome (PRO) measure. The objective of this paper is to determine scale structure and psychometric properties of the Steroid PRO.

Methods: A cross-sectional survey of adults from the UK, USA, Australia and New Zealand, taking glucocorticoids for a rheumatic disease. Initial survey collected demographics, clinical information, 40 Steroid PRO candidate items and EuroQol-5 Dimensions- 5 levels (EQ-5D-5L). Follow-up, 3-5 days later, collected Steroid PRO candidate items and a condition-change ('transition') question. Analysis included Rasch measurement model, exploratory factor analysis (EFA), and hypothesis testing for discriminative validity, convergence validity and test-retest reliability.

Results: Total responses 946: UK n=743 (79%); USA n=139 (15%); Australia/New Zealand n=64 (7%); mean age 57.6 (SD=13.6); 833 (88%) women. Participants with inflammatory arthritis n=197 (21%), connective tissue disease and/or vasculitis n=402 (42%), giant cell arteritis and/or polymyalgia rheumatica n=347 (37%). Twenty-five items were removed due to lack of fit to Rasch model. Of the remaining items, EFA suggested four subscales: Social impact (4 items); Impact on appearance (3 items); Psychological impact (5 items); Treatment concerns (3 items). Rasch modelling supported a four-subscale structure and total score, confirming construct validity and reliability. Hypothesis testing confirmed discriminant and convergence validity. Intraclass correlation coefficient (total score) was 0.809 demonstrating excellent (test-retest) reliability.

Conclusions: The Steroid PRO is a 15-item, valid and reliable scale for measuring the impact of glucocorticoid therapy in people with rheumatic diseases.

Citing Articles

Impact of glucocorticoids on patients' quality of life: a qualitative study assessing face validity and feasibility of the Steroid PRO in patients with inflammatory gastroenterology, respiratory and dermatology conditions.

Sweeney A, Bridgewater S, Orme J, Sattui S, Sharp M, Richards P BMJ Open. 2025; 15(2):e089225.

PMID: 39909511 PMC: 11800201. DOI: 10.1136/bmjopen-2024-089225.

Relationships between patient and physician global assessments in anti-neutrophil cytoplasmic antibody-associated vasculitis.

Bhonsle A, Coughlan T, Graven R, Bussa P, Gingold M, Polkinghorne K Clin Rheumatol. 2024; 44(1):367-375.

PMID: 39671122 DOI: 10.1007/s10067-024-07256-0.

References

Gater A, Nelsen L, Fleming S, Lundy J, Bonner N, Hall R . Assessing Asthma Symptoms in Adolescents and Adults: Qualitative Research Supporting Development of the Asthma Daily Symptom Diary. Value Health. 2016; 19(4):440-50. DOI: 10.1016/j.jval.2016.01.007. View

Tennant A, Conaghan P . The Rasch measurement model in rheumatology: what is it and why use it? When should it be applied, and what should one look for in a Rasch paper?. Arthritis Rheum. 2007; 57(8):1358-62. DOI: 10.1002/art.23108. View

Gorter A, Bakker M, Ten Klooster P, Boonen A, Vonkeman H . The impact of health literacy: associations with disease activity and medication prescription in patients with rheumatoid arthritis. Rheumatology (Oxford). 2023; 62(10):3409-3415. PMC: 10547512. DOI: 10.1093/rheumatology/kead094. View

Black R, Robson J, Goodman S, Hoon E, Lai L, Simon L . A Patient-reported Outcome Measure for Effect of Glucocorticoid Therapy in Adults with Inflammatory Diseases Is Needed: Report from the OMERACT 2016 Special Interest Group. J Rheumatol. 2017; 44(11):1754-1758. DOI: 10.3899/jrheum.161083. View

Yardimci G, Pagnoux C, Stewart J . A Canadian vasculitis patient-driven survey to highlight which prednisone-related side effects matter the most. Clin Exp Rheumatol. 2023; 41(4):943-947. DOI: 10.55563/clinexprheumatol/ef9nda. View

Field J, Holmes M, Newell D . PROMs data: can it be used to make decisions for individual patients? A narrative review. Patient Relat Outcome Meas. 2019; 10:233-241. PMC: 6681163. DOI: 10.2147/PROM.S156291. View

Cheah J, Robson J, Black R, Goodman S, Lester S, Mackie S . The patient's perspective of the adverse effects of glucocorticoid use: A systematic review of quantitative and qualitative studies. From an OMERACT working group. Semin Arthritis Rheum. 2020; 50(5):996-1005. DOI: 10.1016/j.semarthrit.2020.06.019. View

Mathias S, Berry P, de Vries J, Askanase A, Pascoe K, Colwell H . Development of the Systemic Lupus Erythematosus Steroid Questionnaire (SSQ): a novel patient-reported outcome tool to assess the impact of oral steroid treatment. Health Qual Life Outcomes. 2017; 15(1):43. PMC: 5331641. DOI: 10.1186/s12955-017-0609-9. View

Barber M, Drenkard C, Falasinnu T, Hoi A, Mak A, Kow N . Publisher Correction: Global epidemiology of systemic lupus erythematosus. Nat Rev Rheumatol. 2021; 17(10):642. DOI: 10.1038/s41584-021-00690-3. View

10.

Wright B, Linacre J . Observations are always ordinal; measurements, however, must be interval. Arch Phys Med Rehabil. 1989; 70(12):857-60. View

11.

Jones B, Ndosi M, Hunt A, Harcourt D, Dures E . Factors associated with patient activation in inflammatory arthritis: a multisite cross-sectional study. Rheumatol Adv Pract. 2021; 5(Suppl 2):ii35-ii44. PMC: 8570153. DOI: 10.1093/rap/rkab053. View

12.

Bakker M, Putrik P, Rademakers J, van de Laar M, Vonkeman H, Kok M . Addressing Health Literacy Needs in Rheumatology: Which Patient Health Literacy Profiles Need the Attention of Health Professionals?. Arthritis Care Res (Hoboken). 2020; 73(1):100-109. PMC: 7839720. DOI: 10.1002/acr.24480. View

13.

van der Goes M, Jacobs J, Boers M, Andrews T, Blom-Bakkers M, Buttgereit F . Patient and rheumatologist perspectives on glucocorticoids: an exercise to improve the implementation of the European League Against Rheumatism (EULAR) recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis. 2009; 69(6):1015-21. DOI: 10.1136/ard.2009.114579. View

14.

Byron C, Cornally N, Burton A, Savage E . Challenges of living with and managing inflammatory bowel disease: A meta-synthesis of patients' experiences. J Clin Nurs. 2019; 29(3-4):305-319. DOI: 10.1111/jocn.15080. View

15.

Fourie S, Jackson D, Aveyard H . Living with Inflammatory Bowel Disease: A review of qualitative research studies. Int J Nurs Stud. 2018; 87:149-156. DOI: 10.1016/j.ijnurstu.2018.07.017. View

16.

Black R, Goodman S, Ruediger C, Lester S, Mackie S, Hill C . A Survey of Glucocorticoid Adverse Effects and Benefits in Rheumatic Diseases: The Patient Perspective. J Clin Rheumatol. 2017; 23(8):416-420. DOI: 10.1097/RHU.0000000000000585. View

17.

Macdonald G, Koehn C, Attara G, Stordy A, Allerdings M, Leese J . Patient Perspectives on the Challenges and Responsibilities of Living With Chronic Inflammatory Diseases: Qualitative Study. J Particip Med. 2020; 10(4):e10815. PMC: 7434083. DOI: 10.2196/10815. View

18.

Greenhalgh J, Gooding K, Gibbons E, Dalkin S, Wright J, Valderas J . How do patient reported outcome measures (PROMs) support clinician-patient communication and patient care? A realist synthesis. J Patient Rep Outcomes. 2018; 2:42. PMC: 6153194. DOI: 10.1186/s41687-018-0061-6. View

19.

Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D . Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011; 20(10):1727-36. PMC: 3220807. DOI: 10.1007/s11136-011-9903-x. View

20.

Smith Jr E . Detecting and evaluating the impact of multidimensionality using item fit statistics and principal component analysis of residuals. J Appl Meas. 2002; 3(2):205-31. View